Carlos Eduardo Cardoso, Pro-Rector for Research and Technological Innovation at the University of Vassouras, shared on LinkedIn:
“Proton radiotherapy outperforms medulloblastoma irradiation with photons in economic savings in Brazil.
This study aimed to evaluate the cost-effectiveness of proton therapy compared to photon therapy for pediatric medulloblastoma treatment from the payer’s perspective in Brazil, assessing its economic viability and potential to improve long-term outcomes by reducing late complications.
Proton therapy yielded 20.45 QALYs at US$102,933, versus 16.87 QALYs at US$141,971 for photons, with an ICER of -US$22,857/QALY, indicating dominance. PSA showed a mean NMB of US$70,290 (95 % CI: US$42,377–US$98,662), with protons cost-effective in >95 % of simulations. Survival at 30 years was 40.5 % (protons) versus 27.1 % (photons), driven by reduced late effects (e.g., 68 % vs. 45 % cumulative events).
Conclusion: Proton therapy is a cost-effective, dominant strategy for pediatric medulloblastoma in Brazil, offering superior outcomes and cost savings. These findings support its adoption through innovative funding models like public-private partnerships.”
Title: Proton radiotherapy outperforms medulloblastoma irradiation with photons in economic savings in Brazil (PROMISE)
Journal: Dialogues in Health
Authors: Gustavo A. Viani, Carlos Eduardo Cardoso, Ana Carolina Hamamura, Helio A. Salmon, and Gustavo O. Amaral
